Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommaso Matucci

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Research and Reports in Urology|August 11, 2023
Uncommon Haemorrhagic Cystitis of Infectious Origin: A Narrative Review for UrologistsFrancesca Ambrosini, Niccolò Riccardi, Sara Occhineri, et al.
Leukemia & Lymphoma|June 4, 2024
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulationMarco Falcone, Giusy Tiseo, Gabriele Marchetti, et al.
Infectious Diseases and Therapy|November 28, 2022
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic ExperienceGiusy Tiseo, Chiara Barbieri, Valentina Galfo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Research and Reports in Urology|August 11, 2023
Uncommon Haemorrhagic Cystitis of Infectious Origin: A Narrative Review for UrologistsFrancesca Ambrosini, Niccolò Riccardi, Sara Occhineri, et al.
Leukemia & Lymphoma|June 4, 2024
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulationMarco Falcone, Giusy Tiseo, Gabriele Marchetti, et al.
Infectious Diseases and Therapy|November 28, 2022
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic ExperienceGiusy Tiseo, Chiara Barbieri, Valentina Galfo, et al.
Pageof 2